

Statement of Audited Standalone Financial Results for the Quarter & Year Ended on 31st March 2021

Rs. In Lacs other than EPS

		Particulars	Quarter Ended		Year Ended	
			31-03-2021	31-03-2020	31-03-2021	31-03-2020
			Audited	Audited	Audited	Audited
I		Revenue from Operations	2955.95	3027.76	10929.42	11889.09
II		Other Income	125.98	128.70	430.85	421.83
III		Total income (I + II)	3081.93	3156.46	11360.27	12310.92
IV		Expenses				
	(a)	Cost of Materials Consumed	192.17	221.86	678.01	965.21
	(b)	Purchase of Stock-in-trade	327.25	427.45	2013.43	2390.22
	(c)	Changes in inventories of Finished Goods, Stock-in-trade and WIP	231.97	89.81	318.39	-48.74
	(d)	Employee benefit expenses	790.50	947.92	3237.71	3651.02
	(e)	Finance Costs	12.12	12.14	47.37	52.56
	(f)	Depreciation and Amortisation Expense	52.75	56.93	203.54	229.93
	(g)	Other expenses	911.33	711.43	2697.65	2956.94
		Total Expenses (IV)	2518.09	2467.54	9196.10	10197.14
V		Profit before tax (III - IV)	563.84	688.92	2164.17	2113.78
VI		Tax Expense				
	(i)	Current Tax	179.50	176.00	544.50	576.00
	(ii)	Income Tax for previous years	0.00	12.10	8.51	13.89
	(ii)	Deferred Tax	-3.33	39.17	-39.08	36.93
VII		Profit after tax for the period (V-VI)	387.67	461.65	1650.24	1486.96
VIII		Other Comprehensive Income				
	A	(i) Items that will not be reclassified to profit or loss	11.04	-234.29	219.54	-209.68
		(ii) Income Tax relating to Items that will not be reclassified to profit or loss	-59.07	-27.16	-23.58	-23.70
	B	(i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
		(ii) Income Tax relating to Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
IX		Total Comprehensive Income for the period (VII - VIII)	339.64	200.20	1846.20	1253.58
X		Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted	8.45	10.06	35.96	32.40


Notes:

- The above statement of audited standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meeting held on 2nd June 2021.
- The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.
- The figures for the quarter ended on 31st March 2021 are the balancing figures between audited figures for the year ended on 31st March 2021 and published year to date figures upto the third quarter ended on 31st December 2020.
- The figures of the previous year/period have been regrouped/rearranged to render them comparable with figures of the current period.
- The Statement of assets & liabilities as on 31st March 2021 is as per annexure A
- Cashflow Statement as on 31st March 2021 is as per annexure B

Place : Mumbai

Date : 2nd June 2021

 By order of the Board
For Jenburkt Pharmaceuticals Ltd.


(ASHISH U BHUTA)
CHAIRMAN AND MANAGING DIRECTOR

Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai

Annexure - A
Statement of Standalone Assets & Liabilities



			Rs in Lacs	
	Particulars	Note	31/03/2021 Amount	31/03/2020 Amount
	ASSETS			
(1)	Non-current Assets			
(a)	Property, Plants & Equipments	1	850.69	890.00
(b)	Right to Use Asset	2	156.22	198.51
(c)	Goodwill	2	0.14	0.14
(d)	Other Intangible assets	2	47.96	84.13
(e)	Capital Work In Progress	2	37.76	11.81
(f)	Financial Assets			
(i)	Investments	3	650.07	249.67
(ii)	Loans	4	8.14	6.98
(iii)	Other Financial Assets	5	2,285.78	-
(g)	Other Non-current Assets	6	9.10	35.28
(2)	Current assets			
(a)	Inventories	7	758.15	1,089.87
(b)	Financial Assets			
(i)	Investments	8	25.22	157.19
(ii)	Trade Receivables	9	1,400.07	1,782.98
(iii)	Cash and Cash Equivalents	10	249.37	253.40
(iv)	Bank Balance other than (iii)	11	5,401.31	5,515.73
(v)	Loans	12	11.15	21.86
(vi)	Other Financial Assets	13	29.95	27.96
(c)	Other Current Assets	14	116.92	105.28
	Total Assets		12,038.00	10,430.79
	EQUITY AND LIABILITIES			
(1)	Equity			
(a)	Equity Share Capital	15	458.94	458.94
(b)	Other Equity - Reserves & Surplus	16	9,387.69	7,541.49
	LIABILITIES			
(2)	Non-current liabilities			
(a)	Financial Liabilities			
(i)	Lease Liabilities	17	93.97	135.62
(ii)	Other Financial Liabilities	18	296.47	290.84
(b)	Deferred Tax Liability (Net)	19	8.32	23.82
(3)	Current Liabilities			
(a)	Financial Liabilities			
(i)	Lease Liabilities	20	41.66	38.46
(ii)	Borrowings	21	371.06	343.89
(iii)	Trade Payables			
(A)	Total Outstanding dues of Micro Enterprises and Small Enterprises; and	22	2.66	1.85
(B)	Total Outstanding dues of creditors other than Micro Enterprises and Small Enterprises.	22	358.56	520.79
(iv)	Other Financial Liabilities	23	650.95	582.59
(b)	Other Current Liabilities	24	227.02	231.14
(c)	Provisions	25	127.29	217.31
(d)	Current Tax Liabilities (Net)	26	13.41	44.05
	Total Equity and Liabilities		12,038.00	10,430.79

By order of the Board
For Jenburkt Pharmaceuticals Ltd.

(ASHISH U BHUTA)

CHAIRMAN AND MANAGING DIRECTOR

Place : Mumbai
Date : 2nd June 2021

Annexure - B
Cashflow Statement as on 31st March 2021



Rs in Lacs

		31-03-2021	31-03-2020
A.	CASH FLOW FROM OPERATING ACTIVITIES :		
a	Net Profit After Tax	1,650.24	1,486.96
	Adjustments for :		
i	Depreciation and Amortisation Expense	203.54	229.93
ii	Profit on sale/written off of property, plant and equipment and intangible assets, net	(0.17)	-
iii	Tax Expense	513.93	626.82
iv	Finance Cost	47.37	52.56
v	Interest Income	(405.26)	(363.53)
vi	Dividend income	(1.82)	(4.86)
vii	Gain on sale of Investment (Short/Long Term Capital Gain)	(0.08)	-
viii	Provision/write off for doubtful trade receivables/advances	19.20	-
ix	Net unrealised foreign exchange gain	(22.21)	(36.52)
x	Others	(0.69)	-
	Operating profit (Loss) before working capital changes	2,004.05	1,991.36
b	MOVEMENTS IN WORKING CAPITAL		
i	Increase or (Decrease) in Inventories	331.72	(106.75)
ii	Increase or (Decrease) in Trade Receivables	363.70	506.51
iii	Increase or (Decrease) in Other (Current & Non Current) Assets	(11.11)	(9.79)
iv	Increase or (Decrease) in Trade Payables	(161.42)	(132.25)
v	Increase or (Decrease) in Bank Borrowings	27.17	(403.05)
vi	Increase or (Decrease) in Other (Current & Non Current) Liabilities	92.08	236.01
vii	Increase or (Decrease) in Provisions	(117.07)	(33.89)
c	Cash used in operation	2,529.12	2,048.16
i	Income Taxes paid (Net of Refund)	(583.65)	(546.47)
	Net cash used in operating activities (A)	1,945.48	1,501.68
B.	CASH FLOW FROM INVESTING ACTIVITIES :		
i	Payments for purchase of Property, Plant and Equipment (Including Capital Work in Progress, Intangible Assets and Intangible Assets in	(114.51)	(455.44)
ii	Proceeds from disposal of property, plant and equipment and intangible assets	2.97	99.10
iii	Purchase of Investments	(93.28)	(2,125.79)
iv	Proceeds from Sale / Redemption of Investments	72.06	2,256.65
v	Other Bank balances not considered as cash and cash equivalents		
	Bank Fixed Deposit made during the year	(10,909.16)	(5,172.48)
	Bank Fixed Deposit matured during the year	8,782.59	4,885.55
vi	Current & Non Current Financial Loans (Net employee loans given / recovered)	9.53	19.59
vii	Interest Received	369.88	200.40
ix	Dividend Received	1.82	4.86
	Net cash generated by investing activities (B)	(1,878.10)	(287.57)
C.	CASH FLOW FROM FINANCING ACTIVITIES :		
i	Finance Cost	(34.83)	(52.56)
ii	Dividend paid	14.42	(858.19)
iii	Tax on Dividend paid	-	(172.64)
iv	Repayment of Lease Liabilities	(51.00)	-
	Net cash used in financing activities (C)	(71.41)	(1,083.39)
	NET INCREASE/DECREASE IN CASH AND CASH EQUIVALENT (A+B+C)	(4.03)	130.72
	Cash and cash equivalent at the beginning of the year (1st April, 2020)	253.40	122.68
	Cash and cash equivalent as at the end of the year (31st March, 2021)	249.37	253.40
		(4.03)	130.72

By order of the Board
For Jenburkt Pharmaceuticals Ltd.

(ASHISH U BHUTA)

CHAIRMAN AND MANAGING DIRECTOR

Place : Mumbai

Date : 2nd June 2021